Marksans Pharma Ltd.MARKSANS₹253.51 +5.02%

Shares of Marksans Pharma rose over 6% on Monday to an intraday high of ₹256.08, after the company announced that its UK-based subsidiary Relonchem Limited has received marketing authorisation for Sennosides 7.5 mg tablets from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA).

The product is commonly prescribed as a laxative to treat constipation, and its addition strengthens Relonchem’s portfolio of gastrointestinal therapeutics in the UK market. The regulatory clearance allows the company to begin supplying the product in the UK, expanding its reach in a competitive but growing segment.

This is the second regulatory milestone for Relonchem in a span of two weeks. Just last week, the subsidiary secured UKMHRA approval for Gabapentin Oral Solution (50 mg/ml), used in the management of epilepsy and nerve pain. The liquid format of Gabapentin is particularly suitable for patients who have difficulty swallowing solid dosage forms, broadening accessibility for vulnerable patient groups.

The recent approvals are expected to further enhance the company’s revenue visibility and strengthen its positioning in the global generics market.

Over the last three years, Marksans Pharma has given multibagger returns of more than 400%. Let’s take a look at its Factor Analysis scores: 

Note: The stock price mentioned is as of 3:30 PM.

Disclaimer

Investments in securities market are subject to market risks, read all the related documents carefully before investing. This is for informational purposes and should not be considered as recommendations.

Kindly refer to  https://share.market/ for more details.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887, and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. 

Registration granted by SEBI, enlistment as Research Analyst, and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA.

CIN: U65990KA2021PTC146954.